Is hypertriglyceridemia atherogenic?

Presse Med. 2018 Sep;47(9):757-763. doi: 10.1016/j.lpm.2018.08.009. Epub 2018 Sep 24.

Abstract

ASCVD reduction is based on LDL reduction, especially by statins. Highly elevated TG could be harmful, especially because of the risk of pancreatitis. Elevation of TG is mainly due to metabolic disorders and diabetes, alcohol intake and overweight. Genetic factors have been clearly identified in the most severe cases. TG have been generally considered as bystanders for cardiovascular diseases (CVD). Both biological and basic research provide strong data suggesting that TG-rich lipoproteins could be involved in the pathophysiology of CVD. Recent epidemiological and genetics studies strongly corroborate the causal role of TG in CVD. This paves the way for new approaches in the management of patients both for primary and secondary prevention.

Publication types

  • Review

MeSH terms

  • Atherosclerosis / epidemiology
  • Atherosclerosis / etiology*
  • Atherosclerosis / prevention & control
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hypertriglyceridemia / complications*
  • Hypertriglyceridemia / epidemiology
  • Hypertriglyceridemia / therapy
  • Hypolipidemic Agents / therapeutic use
  • Metabolic Diseases / complications
  • Metabolic Diseases / epidemiology
  • Metabolic Diseases / therapy
  • Pancreatitis / epidemiology
  • Pancreatitis / etiology
  • Pancreatitis / therapy
  • Risk Factors

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypolipidemic Agents